Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2019 16:15 ET | Source: Homology Medicines, Inc.

Homology Medicines Reports First Quarter 2019 Financial Results and Recent Highlights

- Received FDA Clearance for IND and Anticipate Starting Phase 1/2 pheNIX Trial for PKU Gene Therapy Candidate with Initial Data Expected by Year End - - Began IND-Enabling Studies for Two Additional...
May 09, 2019 08:30 ET | Source: Homology Medicines, Inc.

Homology Medicines to Present at Bank of America Merrill Lynch Health Care Conference

BEDFORD, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate during a fireside chat...
May 02, 2019 08:00 ET | Source: Homology Medicines, Inc.

Homology Medicines Presents Data from Gene Therapy and Gene Editing Programs and Manufacturing Capabilities at ASGCT Meeting

- Homology’s Scalable HEK293 Suspension Manufacturing Process for AAVHSCs Demonstrated Superiority to a Baculovirus System and AAVHSC15 Showed Improved In Vivo Efficacy Compared to AAV5 in PKU Model -...
April 30, 2019 12:00 ET | Source: Homology Medicines, Inc.

Homology Medicines Presents Data Demonstrating Suite of Novel AAV Vectors Targeted Key Cell Types for Inherited Retinal Diseases

BEDFORD, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data demonstrating that, with...
April 15, 2019 13:05 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces Upcoming Presentations on its Gene Therapy and Gene Editing Platform and Manufacturing Capabilities at the American Society of Gene & Cell Therapy Meeting

BEDFORD, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations highlighting its gene therapy and...
April 09, 2019 19:08 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces Pricing of Public Offering of Common Stock

BEDFORD, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, today announced the pricing of an underwritten public offering of 5,555,556...
April 08, 2019 16:10 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces Proposed Public Offering of Common Stock

BEDFORD, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, today announced that it intends to offer and sell, subject to market and...
April 04, 2019 16:05 ET | Source: Homology Medicines, Inc.

Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production

BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today preclinical data demonstrating that HMI-102, its gene therapy...
April 04, 2019 07:00 ET | Source: Homology Medicines, Inc.

Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU

- Phase 1/2 pheNIX Trial Would Represent First PKU Gene Therapy to Enter the Clinic - - Initial Clinical Data Expected by the End of 2019 - BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) --...
March 19, 2019 08:39 ET | Source: Homology Medicines, Inc.

Homology Medicines to Present at the Alliance for Regenerative Medicine Investor Day

BEDFORD, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present during a fireside chat...